Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) is a multifunctional enzyme best known to many investigators as a`housekeeping' gene used as a loading control on northern blots. Prior studies, however, have shown that GAPDH RNA levels vary greatly among different prostate cancer cell lines. We undertook this study to determine the level of GAPDH gene expression within primary human prostate tumors and to determine the validity of using GAPDH as a loading control for northern analysis of human prostate cancer specimens and normal human organs. We found that GAPDH expression was signi®cantly higher in specimens from patients with pathological stage C and D prostate cancer than those with stage B disease. Within the human prostate cancer cell lines TSUPr1, DU145, LNCaP and PC-3 and a normal neonatal prostate epithelial cell line FNC 267b1, LNCaP cells expressed the highest level of GAPDH but all cell lines, including the normal neonate prostate cell line had very strong GAPDH gene expression. GAPDH RNA levels were highly variable among 16 normal human adult organs and four human fetal organs examined. We conclude that GAPDH RNA levels in human prostate tumors correlate with pathologic stage and that GAPDH should not be used as a loading control in northern blot experiments. Other controls, such as b-actin or 28s ribosomal RNA, would be more suitable for such purposes.
Introduction
Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) is the key regulatory enzyme of glycolysis that generates 1,3-bisphosphoglycerate, a high energy phosphate-containing compound. Since GAPDH is ubiquitous and constitutively expressed, many investigators view it as à housekeeping' gene and it has been used extensively as a loading control on northern blots. GAPDH gene expression, however, is regulated under several circumstances. GAPDH is induced by insulin in adipocytes, 1,2 by interleukin-2 in T-helper lymphocytes, 3 by calcium ionophores in a variety of human cells, 4 by hypoxia 5 and nitric oxide 6 in endothelial cells, by 1,25-dihydroxyvitamin D 3 in malignant human mammary epithelial cell lines, 7 and by thyrotropin in thyroid cells. 8 GAPDH levels also vary during the cell cycle in normal human cells 9 and increase during apoptosis in neurons. 10 Several studies have shown that GAPDH is overexpressed in a variety of tumors and malignant cell lines. 11±16 However, no prior studies have shown a correlation between GAPDH expression in human tumor specimens and pathologic stage.
Recent studies have examined the role of GAPDH in normal and malignant prostate tissues. GAPDH RNA levels vary greatly among Dunning rat prostate tumors and correlate closely with their metastatic potential. 11 Androgen treatment increases GAPDH expression in LNCaP human prostate cancer cells. 17 In addition, there are multiple forms of GAPDH protein in human and rat prostate cancer cells and in normal prostate. 12 The latter studies suggest that GAPDH may play multiple roles in prostate cancer progression. During a recent analysis of primary human prostate tumors of various pathological stages, we observed that GAPDH levels did not correspond to the visualized RNA pattern as detected by ethidium bromide staining of the gels. We undertook this study to determine the validity of using GAPDH as a loading control for northern analysis of human prostate cancer specimens and various normal human organs. We show here that GAPDH gene expression is signi®cantly increased in late pathological stage C and D human prostate tumors compared to those of stage B. In addition, we have determined the level of GAPDH gene expression in four human prostate cancer cell lines, a normal neonatal prostate epithelial cell line and in several normal fetal and adult human organs.
Materials and methods
Prostate tumor tissue and total RNA extraction A total of 24 radical prostatectomy tumor specimens were analyzed: 11 pathological stage B, 8 stage C and 5 stage D. Only one tumor was analyzed from each radical prostatectomy specimen. All tumor specimens were grossly dissected from surrounding normal tissue and adjacent frozen sections of each tumor sample were stained with hematoxylinaeosin and reviewed by a pathologist to contain at least 70% tumor. Total RNA was extracted from the tumor tissues using guanidinium isothiocyanate as previously described. 19 Ten mg of each RNA were treated with 2.5 units DNase (Promega; Madison, WI) at 37 C for 1 h prior to northern analysis.
Cell lines and culture conditions
All cell culture media and supplements were purchased from Gibco BRL (Gaithersburg, MD The three blots containing the human prostate tumor RNAs were hybridized sequentially with the 32 P-labeled probes to GAPDH, b-actin, 28s rRNA and desmin in Rapid-Hyb buffer (Amersham; Arlington Heights, IL). For each of the four hybridizations, all three blots containing human prostate tumor specimens were incubated with the same probe preparation and hybridization solution to ensure that resultant autoradiographs could later be compared to one another. Hybridization with GAPDH, b-actin and desmin probes was performed at 65 C, stringently washed in 2 Â SSC, 0.1% SDS at ambient temperature for 15 min followed by two washes in 0.2 Â SSC, 0.1% SDS at 65 C for 15 min each. Hybridization with the 28s rRNA probe was performed at 50 C, washed at low stringency in 2 Â SSC, 0.1% SDS at ambient temperature for 15 min two times followed by a third wash in 0.2 Â SSC, 0.1% SDS at 42 C for 15 min. The blots were autoradiographed and scanned on a BAS 1000 phosphorimager (Fuji; Japan). Following each hybridization, the blots were washed in 55% formamide, 2 Â SSPE, 1% SDS at 65
C for 1 h, followed by a wash in 1 Â SSC, 0.1% SDS at 65 C for 15 min to remove bound probe.
Northern analysis of human prostate cancer cell lines and normal human neonatal prostate cells
Eight mg of DNase-treated total RNAs from the cell lines were separated on a denaturing formaldehydea1% SeaKem LE agarose gel and transferred onto Maximum Strength Nytran. The blot was hybridized sequentially with random-primed, 32 P-labeled probes to GAPDH and b-actin and analyzed as described above.
Northern analysis of normal human organs
Human multiple organ northern blots (CLONTECH; Palo Alto, CA) that contain 2 mg of poly(A ) RNA from adult pancreas, kidney, skeletal muscle, liver, lung, placenta, brain, heart, peripheral blood leukocyte, colon, small intestine, ovary, testis, prostate, thymus and spleen and fetal kidney, liver, lung and brain were hybridized sequentially with random-primed, 32 P-labeled probes to GAPDH and b-actin and analyzed as described above.
Relative GAPDH signal intensity calculation
To normalize for RNA loading, the phosphorimage data of each sample (pixilsamm 2 Àbackground pixilsamm 2 ) was divided by the corresponding b-actin or 28s rRNA phosphorimage data of each sample (pixilsa mm 2 Àbackground pixilsamm 2 ) to yield a ratio of GAPDHab-actin or GAPDHa28s rRNA expression. The sample with the highest normalized GAPDH ratio was assigned a relative signal intensity of 1.00 (100%). All other samples within the group were then divided by the GAPDHa b-actin or GAPDHa28s rRNA ratio of this highest expressing sample to produce a relative GAPDH signal intensity for each sample analyzed.
Statistical analyses
Statistical analyses on all relative GAPDH signal intensity data were performed on a 486 IBM personal computer using the SPSS statistical software package for MS Windows 6.1. All data were ®rst examined using the Levene Test for homogeneity of variance. The b-actin normalized average relative GAPDH signal intensity data required non-parametric analyses. Therefore, the data were analyzed for statistical signi®cance using Kruskal-Wallis oneway ANOVA, followed by Mann-Whitney Wilcoxon Rank Sum posthoc comparisons. The 28s rRNA normalized average relative GAPDH signal intensity data were suitable for one-way ANOVA, followed by Tukey's Honestly Signi®cant Difference posthoc comparisons. For all tests, the signi®cance level was assigned at P 0.05.
Results

GAPDH expression in human prostate tumors
We prepared northern blots containing DNase-treated total RNA from 11 pathological stage B, 8 stage C and 5 stage D primary human prostate tumors that were obtained from radical prostatectomy specimens. None of the patients received hormonal or other anti-cancer treatments preoperatively. We sequentially hybridized these blots with 32 P-labeled probes to GAPDH and b-actin. Representative results from the northern analysis of the human prostate tumors for GAPDH expression are shown in Figure 1 . Three of the specimens from patients with stage B cancer had nearly undetectable levels of GAPDH expression, while the remaining four had relatively low levels, when normalized to b-actin, as compared to stage C and D patients. Similar results were obtained for the other two patient sample blots (data not shown).
To con®rm the accuracy of b-actin as a loading control, we also hybridized the blots with a 32 P-labeled oligo to 28s rRNA. The 28s rRNA oligo hybridization pattern was similar to that of the b-actin probe but resulted in a higher background (data not shown). We have compared the average relative GAPDH signal intensities of stage B, C and D human prostate tumors following b-actin and 28s rRNA normalization (Figure 2 ). Stage C and D tumors expressed signi®cantly higher GAPDH expression levels (P 0.05) than stage B tumors, regardless of the probe used to normalize for loading. Based on the results of this comparison, we have used b-actin normalization for the remainder of the present study since its hybridization can be performed at high stringency and yields low background signal.
GAPDH expression in human prostate cancer cell lines
Given that signi®cantly increased GAPDH gene expression was found in human prostate tumors of advanced pathological stage, we expanded our study to determine the levels of GAPDH expression in TSUPr1, DU145, LNCaP and PC-3 human prostate cancer cell lines that were established from metastases. In addition, we also determined the level of GAPDH expression in FNC 267 b1, a normal neonatal prostate cell line immortalized by SV40 Large T antigen. 19 Figure 3 shows the results of the northern analysis for GAPDH in the four human metastatic prostate cancer cell lines and in FNC 267 b1 cells. Following normalization to b-actin, the LNCaP cell line had the highest relative GAPDH expression. However, GAPDH expression was very strong in all of the cell lines, Figure 1 Northern blot analysis of GAPDH gene expression in pathologic stage B, C and D primary human prostate tumors. Ten mg of DNase-treated total RNAs from stage B, C and D prostate tumors were separated on a denaturing formaldehydea1% SeaKem LE agarose gel and transferred onto Maximum Strength Nytran. The blot was hybridized with a random-primed, 32 P-labeled probe to GAPDH, stringently washed and autoradiographed with intensifying screens for 18 h. The GAPDH probe was removed from the blot and the blot was re-hybridized with a random-primed, including the normal neonate cells (Figure 3 ; 1 h exposure). This high level of GAPDH expression in the human prostate cancer cell lines is consistent with the increased levels detected in the later stage primary prostate tumors in Figures 1 and 2 since these cell lines were derived from prostate cancer metastases that probably originated from late stage primary tumors.
GAPDH expression in normal human organs
To determine the level of GAPDH expession in normal adult prostate and other normal adult and fetal organs, we hybridized multiple organ northern blots containing poly (A ) RNA from several fetal and adult organs with 32 P-labeled probes to GAPDH and b-actin (Figure 4) . It is apparent from Figure 4 that GAPDH levels were highly variable according to organ type. Skeletal muscle had the highest signal relative to the other seven organs on the same blot (Figure 4) . In a separate experiment, a blot containing RNA from four human fetal organs was hybridized together with one containing eight additional human adult organs, including normal prostate ( Figure  4 ). This approach allowed us to directly compare GAPDH expression in fetal organs to that in adult organs. We again found that GAPDH expression varied according to organ type. In addition, fetal organs had consistently higher relative GAPDH levels, which were up to ®ve-fold greater than those of adult organs analyzed under identical conditions (Figure 4) .
After ®nding that skeletal muscle had relatively high GAPDH expression (Figure 4) , and since skeletal and smooth muscle ®bers are common within the ®bromus-cular stroma of the prostate, 20 we addressed the possibility that the high GAPDH levels measured for stage C and D tumors (Figures 1 and 2) were simply a re¯ection of high muscle content instead of elevated GAPDH expression within the cancer cells themselves. We therefore rehybridized the three northern blots containing patient specimens with a 32 P-labeled probe to desmin which is expressed speci®cally in muscle. We found that desmin RNA levels did not correlate with tumor stage (P 0.347), indicating that muscle content was not a confounding variable in the analysis of patient specimens (data not shown).
Discussion
We show here a correlation between GAPDH gene expression and pathologic stage for patients with prostate cancer. Average GAPDH RNA levels for stage C and D human prostate cancer specimens were signi®cantly higher than those for stage B specimens (Figures 1 and  2 ). GAPDH expression was also very high in all four human metastatic prostate cancer cell lines (Figure 3) . Previous studies have shown that GAPDH expression is increased in other human tumors and tumor-derived cell lines from colon, kidney, liver, lung and pancreas 13, 14, 16 . However, the current study is the ®rst to show a relationship between GAPDH expression and cancer stage. The fact that we found statistically signi®cant differences between stages despite the small sample size suggests that GAPDH is worthy of further study as a possible diagnostic or prognostic marker. Further studies will also be required to determine whether GAPDH actually has a primary role in prostate cancer progression, as suggested by previous studies, 11, 12 or whether its overexpression is simply a re¯ection of other genetic changes characteristic of tumors.
We also found that GAPDH RNA levels were highly variable in a variety of normal human organs (Figure 4 ). RNA from adult pancreas, kidney, skeletal muscle, liver, lung, placenta, brain and heart was hybridized with a 32 P-labeled probe to GAPDH, stringently washed and autoradiographed with intensifying screens for 18 h. The GAPDH probe was removed from the blot and the blot was re-hybridized with a 32 Plabeled probe to b-actin, stringently washed and autoradiographed with intensifying screens for 7 h. B. The relative GAPDH signal intensities were calculated following b-actin normalization and phosphorimage analysis. GAPDH was expressed highest in adult skeletal muscle and heart. C. Human multiple organ northern blots (CLONTECH, Palo Alto, CA) that contain 2 mg of poly (A ) RNA from adult peripheral blood (PB) leukocyte, colon, small intestine, ovary, testis, prostate, thymus and spleen and fetal brain, kidney, liver and lung were hybridized sequentially with 32 P-labeled probes to GAPDH and b-actin and processed as described above. D. The GAPDH signal intensities were highest in all of the fetal organs examined relative to the adult organs, including normal prostate.
All four fetal organs tested had high GAPDH expression relative to adult organs, consistent with the fact that high rates of aerobic glycolysis prevail during fetal development. 21 We found that, unlike GAPDH levels, 28s rRNA levels and b-actin levels correlated closely with total RNA loading for tumor specimens, cancer cell lines and normal tissues. Relative GAPDH RNA levels were therefore probably not simply a re¯ection of variations in 28s rRNA or b-actin expression. Our results and those of earlier studies 1±17 suggest that GAPDH should not be used as a control for RNA loading. Since 28s rRNA has been studied more thoroughly than b-actin in this regard 22±24 28s rRNA is the preferable loading control. Previous studies have shown that GAPDH protein levels are extremely heterogeneous in different cancer foci within individual human radical prostatectomy specimens. 12 We cannot conclude from the present studies whether GAPDH RNA levels are similarly heterogeneous, since GAPDH is regulated in part at the posttranscriptional level 17, 25 . Some tumors may contain small foci with much higher GAPDH RNA levels than the remainder of the specimen. Tumors may also vary with regard to the numbers and types of normal cells they contain and the levels of GAPDH expressed by normal cells. We plan to address these issues in future experiments by using in situ hybridization and image analysis. Despite the inherent limitations of northern analysis, our studies suggest that GAPDH may have a role in prostate cancer progression and may be a marker of advanced disease. However, a much larger study will be required to con®rm the observed correlation between stage and GAPDH RNA levels and to determine whether GAPDH has any clinical utility.
